ARS Pharmaceuticals, Inc. SPRY Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s stock issuance proceeds?
- ARS Pharmaceuticals, Inc. (SPRY) reported stock issuance proceeds of $62K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s stock issuance proceeds changed year-over-year?
- ARS Pharmaceuticals, Inc.'s stock issuance proceeds decreased by 91.4% year-over-year, from $725K to $62K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s stock issuance proceeds?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a 115.2% compound annual growth rate (CAGR), from $570K to $5.68M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.